At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder (SUD), and was the first PDT to receive marketing authorization from the FDA to treat disease.

Q&A with Pear Therapeutics

Q: What is the story behind the central idea that inspired the creation of your organization/company?

A: Our CEO, Dr. Corey McCann, founded Pear in 2013. A neuroscientist by training, Dr. McCann was working as a venture capitalist in the digital health space and saw a clear opportunity to do better for patients by combining leading technology with cutting-edge biotechnology. After conducting an exhaustive review of existing research, he founded Pear Therapeutics and began to in-license the most promising development assets. Today Pear operates at the intersection of biology and software technology, where clinicians and researchers work side-by-side with engineers and developers. 

Q: What's the most inventive, innovative, or disruptive aspect of your initiative?

A: Pear is truly a company of "firsts." We are leading the development of a new segment in the healthcare industry, prescription digital therapeutics, or PDTs."

In September 2017, Pear became the first company to receive FDA authorization for a prescription digital therapeutic to treat disease with the market authorization of reSET® for the treatment of Substance Use Disorder. Our second product, reSET-O™ for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation by the FDA and is currently under review. Pear is one of nine companies helping the FDA to evaluate regulation for PDTs, as a participant in its digital health software pre-certification pilot program, established in September 2017.

Q: What single word or phrase best describes the culture of your startup and why?

A: Redefining Medicine.